Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

<jats:p>&lt;p&gt;Representativeness of study participants.&lt;/p&gt;</jats:p>

section_content: Patients had disease that relapsed or was refractory/intolerant to prior standard therapy, and most patients with CLL/SLL had intermediate, high, or very high-risk disease. 

Patients with hairy cell leukemia (HCL) and Castleman disease-which are rare lymphoproliferative diseases-were also enrolled, and the study drug showed benefit. 

Overall The patients in this study were heavily pretreated, and most had high-risk disease.
section_name: Other considerations